Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2005-12-29
- Last Posted Date
- 2012-03-20
- Lead Sponsor
- Accelerated Community Oncology Research Network
- Target Recruit Count
- 30
- Registration Number
- NCT00270894
- Locations
- 🇺🇸
Arena Oncology Associates, Great Neck, New York, United States
🇺🇸Advanced Medical Specialties, Miami, Florida, United States
🇺🇸Northwest Georgia Oncology Centers, PC, Marietta, Georgia, United States
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-11-28
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 49
- Registration Number
- NCT00258960
- Locations
- 🇪🇸
Hospital Puerta del Mar, Cadiz, Spain
🇪🇸Hospital Clinic i Provincial, Barcelona, Spain
🇪🇸Hospital Juan Canalejo, La Coruña, Spain
Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT00258349
- Locations
- 🇺🇸
Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States
🇺🇸Iowa Methodist Medical Center, Des Moines, Iowa, United States
🇺🇸Woodwinds Health Campus, Woodbury, Minnesota, United States
Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2018-03-02
- Lead Sponsor
- Rita Sanghvi, Mehta
- Target Recruit Count
- 48
- Registration Number
- NCT00256243
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
Neoadjuvant Treatment of Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 43
- Registration Number
- NCT00254592
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2013-08-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 120
- Registration Number
- NCT00242203
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-02
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 11
- Registration Number
- NCT00216073
- Locations
- 🇺🇸
Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Quality Cancer Center (MCGOP), Indianapolis, Indiana, United States
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 7
- Registration Number
- NCT00216047
- Locations
- 🇺🇸
Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Center for Cancer Care at Goshen Health System, Goshen, Indiana, United States
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-12-27
- Lead Sponsor
- Kari Kendra
- Target Recruit Count
- 10
- Registration Number
- NCT00201760
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00193089
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.